Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

is increase was tempered by the non- recurrence of severance costs incurred in the second quarter of 2007, lower expenses related to the sales and marketing of Megace(R) ES and lower bonus and stock-based compensation.

2008 Financial Guidance

Par has adjusted its previously announced guidance for full-year 2008 earnings per diluted share from continuing operations of $0.65-$0.85 to ($0.06)-$0.38 reflecting the pricing pressure on the Company's generic business experienced in the second quarter, a challenging reimbursement environment for Megace(R) ES and higher legal costs. The Company's projections are based on its results for the first six months of 2008 and the impact of recent new product launches, as well as management's estimates regarding the impact of product competition on existing products and anticipated legal costs. This EPS range excludes anticipated pre-launch spending and milestone payments in support of Strativa's business strategy and includes the estimated impact of three potential new generic product launches (i.e., sumatriptan kits, clonidine, and certain strengths of risperidone ODT) with an expected fully diluted EPS impact of $0.24-$0.39. These estimates are, of course, subject to future developments, not all of which may be anticipated at this time.

Conference Call

Par has scheduled a conference call for Friday, August 8 at 9:00 am ET to discuss results for the second quarter of 2008. Par invites investors and the general public to listen to a webcast of the conference call. Access to the live webcast can be made via the Company's website at http://www.parpharm.com. The dial-in numbers for the conference call will be 888-713-4213 for domestic callers and 617-213-4865 for international callers. The passcode is 56885024. A replay of the conference call will be available for two weeks approximately one hour after the call. The dial-in numbers for the replay are 888-2
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Synthetic Biology Market 2014-2018" report to their offering. ... The term synthetic biology covers the designing and engineering ... well as the redesigning of natural biological systems that ... be a form of extreme genetic engineering because it ...
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/28/2014)... July 28, 2014 The National Model ... Muncie IN, is pleased to announce that it has ... Museum of the United States Air Force. , The ... process that concluded this spring with an on-site inspection ... OH museum. , The National Museum of the ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... epigenetic anticancer program at Pharmion ... inhibitors - ... Significant opportunity to explore combination epigenetic therapies, BOULDER, Colo. ... and MethylGene Inc. (TSX: MYG) today announced a,research collaboration for ...
... /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: ... increased more than,35% over the first quarter of 2007 ... for the same period in the previous year. ... compared to only,$24,374 in the first half of 2006. ...
... COLUMBIA, Md., Aug. 14 Martek Biosciences,Corporation announced that ... of fiscal 2007 on September 5, 2007, at approximately ... 4:45 p.m. EDT Martek,will hold a conference call to ... with investors. The call is expected to be approximately ...
Cached Biology Technology:Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 3Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 4Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 5Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 6Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6Martek to Announce Third Quarter 2007 Results on September 5, 2007 2
(Date:7/28/2014)... Wyss Institute for Biologically Inspired Engineering at Harvard ... will be commercialized by a newly formed private ... and personalized medicine products. The announcement ... of Technology Development (OTD) and the start-up Emulate ... automated human Organs-on-Chips platform. , "This is ...
(Date:7/27/2014)... that nicotine and cotinine, a metabolite of nicotine, can ... in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is ... ends up in the tobacco smoke. Once inhaled, it ... is activated by a variety of enzymes called Cytochrome ... nicotine can partially interfere with the activation of NNK, ...
(Date:7/27/2014)... of mayfly in the southern Western Ghats, a mountain range ... the first time that any mayfly belonging to the genus ... The new species, called Labiobaetis soldani , "is named ... to the understanding of the Ephemeroptera of Palaearctic and Oriental ... the new mayfly in the Journal of Insect Science ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... The discovery by Uppsala University researchers of a previously ... ways brings new potential for early diagnosis of a ... the Web edition of the American journal Proceedings ... provide new knowledge of the cause of common diseases ...
... native fishes in the Pacific Northwest are threatened or ... are expended annually on researching their populations and on ... been directed toward to the impacts of habitat alteration, ... published in the March 2009 issue of BioScience ...
... Society for Clinical and Economic Aspects of Osteoporosis and ... scientific programme for the upcoming IOF WCO- ECCEO10, a ... May 5-8, 2010. Complete programme information, online ... www.iofwco-ecceo10.org . IOF WCO-ECCEO10 will offer ...
Cached Biology News:World Congress on Osteoporosis 2010 presents outstanding scientific program 2
...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... Protein Extraction Reagent is a ... that means no scraping, no ... With M-PER Reagent, rapid lysis ... at room temperature, yielding 25% ...
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
Biology Products: